

MoP Methodological Note

ABPI Clause 30 Disclosure of Contracted Services Provided by Members of the Public, Including Patients and Journalists

This disclosure has been prepared in accordance with Clause 30 of the Association of the British Pharmaceutical Industry (ABPI) Code of Practice and relates to contracted services provided by members of the public, including patients and journalists, during the reporting period.

Reporting Period

This disclosure covers payments made between 1 January 2025 and 31 December 2025.

Scope

The disclosure includes fees and reimbursed expenses paid to members of the public who were contracted to provide legitimate services to the Company. Such services may include, but are not limited to:

Participation in advisory boards.

Speaking or presenting at meetings or events.

Reviewing educational or patient materials.

Attendance at workshops or consultation meetings.

Participation in market research where a written contract and payment were in place.

Other consultancy or advisory activities.

Payments are disclosed in aggregate for the following recipient groups:

Members of the public

Patients

Journalists

Individuals are not identified by name, in accordance with the requirements of Clause 30.

Fees and Expenses

Fees for services and reimbursed expenses are reported separately.

Fees include payments for professional services provided under a written contract.

Expenses include reasonable travel, accommodation, subsistence and other out-of-pocket costs reimbursed in connection with the contracted services.

Timing of Disclosure

Payments are reported in the calendar year in which they were made, regardless of when the contracted activity took place.

Currency

All payments are reported in pounds sterling (£). Where payments were made in another currency, they have been converted to pounds sterling using the Company's standard financial exchange rate applicable at the time of payment.

Taxes

Amounts disclosed represent gross payments before deduction of any applicable taxes. Where Value Added Tax (VAT) applies, the Company's standard accounting policy has been applied.

Data Quality

The Company has implemented internal processes designed to ensure that disclosures are complete, accurate and consistent with the requirements of the ABPI Code. Any corrections identified after publication will be updated as appropriate.

Publication

This disclosure is published annually on the Company's website in accordance with the ABPI Code of Practice.

Signed:

Magarete Ruiz

Bial Pharma UK Ltd

Senior Director, Country Manager UK&IE